GlassScriptPhysician profile
Michael D Schonefeld
NPI 1245210590
$4,029.52
in general payments reported to CMS, 2019-2025
21 companies · $860 in 2025
The $860 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $404 · 2021: $665 · 2022: $921 · 2023: $750 · 2024: $197 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,707 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,706.67 |
| Education | $100.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $544.74 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $472.60 | 2019-2022 | |
| Akebia Therapeutics INC | $453.17 | 2019-2025 | Vafseo, Auryxia |
| Astrazeneca Pharmaceuticals LP | $382.81 | 2019-2024 | Farxiga |
| Fresenius USA Marketing, INC. | $328.80 | 2019-2025 | Velphoro, Velphoro |
| Medtronic, INC. | $276.87 | 2022-2023 | Ellipsys Vascular Access System |
| Otsuka America Pharmaceutical, INC. | $272.71 | 2020-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $254.68 | 2022-2024 | |
| Amgen INC. | $241.03 | 2021-2023 | Parsabiv |
| Ardelyx, INC. | $232.51 | 2024-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $154.36 | 2021-2025 | Lupkynis |
| Vifor Pharma, INC. | $135.20 | 2019-2023 | Veltassa |
| Opko Pharmaceuticals, LLC | $67.32 | 2025 | Rayaldee |
| Glaxosmithkline, LLC. | $49.42 | 2021 | |
| Scpharmaceuticals INC. | $29.15 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $27.51 | 2020-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $26.94 | 2019-2020 | |
| Abiomed | $24.33 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $20.06 | 2021 | |
| Mallinckrodt Hospital Products INC. | $17.71 | 2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.60 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schonefeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.